Clinical trial
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction…
NCT00434434 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00434434 |
|---|---|
| Title | A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma |
| Official title | A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lyophilized and Aged Liquid Omalizumab in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma |
| Acronym | AQUA |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Allergic Asthma |
| Intervention type | Drug |
| Interventions | omalizumab, placebo |
| Enrollment | 61 |
| Start date | Oct 1, 2007 |
| Primary completion | Feb 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Feb 13, 2007 |
| Last update posted | Dec 14, 2022 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: